There is a need for researchers to have easy reference to the wide spectrum of different types of quality of life (QoL) instruments that can be used in atopic dermatitis (AD). Previous reviews on QoL in AD do not cover the full spectrum of QoL measures used in studies on AD. This study, on behalf of the European Academy of Dermatology and Venereology (EADV) Task Force on QoL, contains information on instruments available for health-related QoL and family QoL assessment in AD including information on validation, experience of QoL assessment in AD for different purposes, peculiarities of QoL assessment in different age groups, expert analysis of available instruments including data on limitations of their use and recommendations of the Task Force.
Introduction
There is a need for researchers to have easy reference to the wide spectrum of different types of quality of life (QoL) instruments that can be used in atopic dermatitis (AD). Previous reviews on QoL in AD do not cover the full spectrum of QoL measures used in studies on AD. 1 A recent review on QoL instruments in adult AD 2 did not identify a specific QoL instrument to be recommended for use in adult AD patients. This study, on behalf of the European Academy of Dermatology and Venereology (EADV) Task Force (TF) on QoL, contains information on instruments available for health-related (HR) QoL and family QoL assessment in AD including information on validation, experience of QoL assessment in AD for different purposes, peculiarities of QoL assessment in different age groups, expert analysis of available instruments including data on limitations of their use and recommendations of the Task Force. Although we do not attempt to define the 'best' QoL instrument, the information provided should help dermatologists and researchers to choose appropriate QoL instruments and avoid common mistakes.
Methods
Members of the European Task Force on Atopic Dermatitis were invited to participate and Prof. Oranje agreed to join the working group. The literature search was performed using the 6 • Children (self-assessment version and a proxy version)
• 24 items • Six dimensions: physical well-being, emotional well-being, self-worth, well-being in the family, well-being related to friends/peers and school-related well-being 
Results

HRQoL and family QoL instruments in AD
A list of generic, dermatology-specific and AD-specific instruments with brief descriptions and information on validation are Quality of life measurement in atopic dermatitis presented in Tables 1-3 . In several publications, 42, 43 the names of the QoL instruments used are not given. In some other studies, unvalidated 'study-specific' instruments were used, some brief and simple [44] [45] [46] [47] and others more complicated. [48] [49] [50] [51] [52] A 'modified' DLQI was used in one study to measure the impairment of 'itchrelated' QoL. 53 Some QoL instruments with non-English original versions are given alternative titles in different publications. For example, Fragebogen Alltagsleben (FAL), ALLTAG and 'Daily life' are alternative titles of the same German instrument. 16 QoL assessment in different age groups of patients with AD
We did not find information concerning specific aspects of HRQoL that may be affected differently in different age groups of adults with AD. There are several AD-specific HRQoL instruments created especially for children. Most studies on QoL in young AD patients used the Infants Dermatitis Quality of Life Index (IDQoL). 31 However, other AD-specific proxy instruments, the Childhood Atopic Dermatitis Impact Scale (CADIS) encompassing mixed proxy and family QoL 37 and the Childhood Impact of Atopic Dermatitis (CIAD) 40 were also used. The most widely used instrument for self-assessment of HRQoL in children with AD is the dermatology-specific Children's Dermatology Life Quality Index (CDLQI). 18 Several generic instruments have also been used to assess QoL of AD children: these include Fragebogen f€ ur KINDer und Jugendlichezur Erfassung der gesundheitsbezogenen Lebensqualit€ at (KINDL), 6 Quality of Life Scale for Children (AUQEI), 7 DIS-ABKIDS Chronic Generic Measure (DCGM-37), 10 Pediatric
Quality of Life Inventory (PedsQL), 15 V ecu et Sant e Perc ßue de l'Adolescent (VSP-A), 14 Children's Quality of Life Index (CLQI), 17 FAL/ALLTAG 16 and AD-specific DISABKIDS AD Module (ADM). 36 Because the lives of children alter greatly between the ages of 4 and 16 years, in the consideration of HRQoL children are not a homogenous group. Jirakova et al.
54
divided children into two age groups, 7-13 years and 14-18 years, and found significant differences in two CDLQI items: problems in playing and doing hobbies and problems during school or holidays. Several AD-specific family QoL instruments have been created to try to measure the secondary impact of having someone in the family with AD on the QoL of other family members. These include the Dermatitis Family Impact (DFI), 34 Quality of life in Primary Caregivers of Children with AD (QPCAD), 35 Parents'
Index Quality of Life-AD (PIQoL-AD), 38 The Quality of Life in Parents of Children with AD 39 and CADIS (mixed proxy and family QoL instrument). 37 The dermatology-specific Family
Dermatology Life Quality Index (FDLQI) was created to measure the impact in family members of patients with all skin diseases and from all age groups. 19 The FDLQI may be as effectively used by parents of children with AD as it can be used by family members of adult dermatology patients. 55 The scores of 33 teenagers with AD were presented as part of the data used for validation of the dermatology-specific Skindex-teen questionnaire. 56 The generic HRQoL instrument for adolescents, VSP-A, was used in French children during the validation of the DISAB-KIDS instrument. 10 The dermatology-specific CDLQI questionnaire 57 has been used to study the specific problems experienced by adolescents.
Use of QoL measures in unvalidated or inappropriate age groups An important issue is the quite frequently reported use of HRQoL instruments out of their validated age limits. For example, Skindex-29, an instrument for adults, was used in children from 13 years old 58 and the DLQI, designed for use in those over 16 years old, was used in children from 8 years old. 59 The CDLQI, originally validated for use in children from 4 to 16 years old, was used in children aged 3 years, 60 2 years [61] [62] [63] [64] and even 1 year of age. 65, 66 The IDQoL has been used in children under 6 54 and 7 years of age, 67 although it is only meant to be used in infants. Using this measure in older children was explained as being necessary because of the education system in the Czech Republic. 54 The IDQOL is recommended to be used by children aged from newborn to 3 years of age and CDLQI by children from 4 to 16 years of age. The lower age cut-off was chosen because of the way in which a 4-year-old behaves and the relevance of the questions to this age group. Although reasons were given 54 why in a study in the Czech Republic different age limits were applied for the use of the IDQoL and CDLQI, the original validated age recommendations remain those recommended by the authors.
Reasons for assessment of QoL in AD
Clinical trials Several different QoL instruments have been used in clinical trials of AD as outcome measures (Table 4) . The DLQI and CDLQI have been the most frequently used, and the IDQoL and DFI are the most widely used AD-specific and infant and family QoL instruments. In some clinical trials, 'study-specific' nonvalidated instruments were used. 45, 47, 49, 119 Reports of other trials do not contain information on which HRQoL instruments were used.
42,120
Impairment of HRQoL and family QoL Several questionnaires were used simultaneously in studies of how QoL is impacted in AD patients and their families (Table 4) .
Creation and validation of instruments Several publications describe the creation and validation of QoL instruments, and their culturally validated local versions, in AD patients and in parents/caregivers (Table 4 ). The DLQI, DFI and PIQoL-AD have also been used in the validation process of non-QoL instruments. • Responses are on a seven-point Likert • All responses are transformed to a linear scale of 100, varying from 0 (no effect) to 100 (effect experienced all the time). Skindex scores are reported as three scale scores, corresponding to the three domains; a scale score is the average of a patient's responses to items in a given domain
• Quality of life measurement in atopic dermatitis 
123,124
Educational programmes The QoL instruments that have been used to assess the efficacy of different educational programs are given in Table 4 . The impact of support groups on HRQoL has been measured using the CDLQI, improving personal relationships and leisure time. 103 DFI scores suggested that involvement with support groups 103 or undertaking a 2-day parental education programme 134 is not enough to improve family QoL. However, the importance of intensive educational programmes in children (5-16 years old) was confirmed by an improvement in the IDQOL, CDLQI and DFI scores. 135 Web-based education programmes had a beneficial effect on the HRQoL of AD children, as measured by the IDQoL. 136 Parental counselling sessions about medical, nutritional and psychological issues improved treatment habits, costs and coping strategies in a study using the FAL/ALLTAG questionnaire. 107 Another German questionnaire 'QoL in parents of children with atopic dermatitis' was used to analyse the impact of longer educational programmes for parents of AD children and teenagers. There were better results in children less than 7 years old. 137 The same measure was used to show that child-parent interventions could change the psychological parameters that could influence adherence and the success of therapy, by improving their coping strategies for control of scratching. 105 Six weekly meetings as part of a multidisciplinary approach involving a paediatric allergist, dermatologist and psychologist had a significant improvement on IDQOL and DFI scores, also decreasing the levels of parents' anxiety. 104 DLQI and CDLQI scores have revealed the impact of daily text messages for 6 weeks as medication reminders and education for teens and adults. 138 The online self-management programme 'Living with eczema' improves DLQI scores. 139 DLQI and SCORAD scores were significantly improved by referral of atopic adults to secondary care, probably due to decreasing worries and concerns regarding their disease.
140
Impact of AD and other diseases Generic and dermatologyspecific HRQoL instruments that have been used to compare the impact of AD and other diseases are given in Table 4 . These studies confirmed that AD has a high impact on social functioning and psychological well-being, similar to other chronic dermatological conditions (psoriasis, Darier's disease and Hailey-Hailey disease), hypertension, depression and type II diabetes. 141 The use of the DLQI, Skindex-29 and the EQ-5D in large population studies showed lower QoL in people with self-reported skin diseases (including AD) than in the general population. 108 Chronic diseases such as AD had a higher impact on QoL, as measured by the CDLQI and AUQEI, than molluscum contagiosum. 117 In children, AD and psoriasis result in the highest CDLQI scores, followed by urticaria and acne. 17 Vitiligo may cause greater impairment of HRQoL, assessed by the CDLQI, than AD. 109 Generalized AD resulted in greater impairment of QoL than severe systemic diseases such as cystic fibrosis, asthma, epilepsy or diabetes. 17 Skindex-29 scored more highly in AD than in 'intrinsic AD'. 58 Use of the KINDL-R showed that acute AD and hay fever could have a higher impact on QoL than asthma. 113 Young, single, poor patients with a long duration of AD, psoriasis, Quality of life measurement in atopic dermatitis 142 Use of the generic measure, SF-12, has shown that psoriasis patients may experience a greater impact on their QoL and higher perceived stress than AD patients. 112 Using the DLQI and Skindex-16, it was shown that psoriasis has a higher effect on desire to be with people, showing affection and causing more problems with the treatment, whereas in AD itching causes higher negative impact on QoL. Psoriatic patients with only mild disease may experience a large negative effect on their QoL, a scenario not typical for AD patients. 110 A study using the Adjustment to Chronic Skin Diseases Questionnaire (ACSD) suggested that the impact of psoriasis is greater than that of AD. 118 Another study showed that only arthropathic psoriasis had a higher impact on HRQoL than AD, as measured by the SF-36 and the DLQI. 143 DLQI measurement showed that in both psoriasis and AD, hospitalization could have a positive effect on QoL. 144 The willingness to pay in both AD and psoriasis correlates with DLQI scores. 145 DLQI scores are better correlated with measures of depression, anxiety and personal interactions in AD than in vitiligo or healthy controls.
146
Other reasons to assess QoL in AD Other studies where QoL of AD patients and/or their families was studied are given in Table 5 .
Discussion
The use of a wide range of QoL instruments has confirmed the impairment of QoL experienced by AD patients and their family members. Despite there being a range of reported correlations between HRQoL instruments and AD severity measures, 128, 129 it is clear that HRQoL is generally more impaired in patients who have a more severe clinical course of AD. Generic instruments should be used to compare QoL impairment in AD with nondermatologic conditions: dermatology-specific instruments may be used to compare QoL across different skin diseases. However, Twiss and McKenna 176 used two disease-specific instruments that were created on the same principles (PSORIQoL and QoLIAD) to compare QoL impairment in AD and psoriasis. Dermatology-specific and disease-specific questionnaires may have a greater capacity for differentiation and be more sensitive to change than generic measures. Using a questionnaire which is not specifically tailored to the disease could mean that some issues associated with the disease are not recorded. 177 When the generic SF-36 was used in AD, there were only small score differences between patients with mild and moderate eczema and between mild eczema and healthy controls, and no significant correlation with AD severity, in contrast with reported correlations using the dermatology-specific DLQI and CDLQI. 178 There are many types of validated HRQoL instruments. Questionnaires should be tested for scale structure, reliability, validity and responsiveness. Additional validation methods are used to assess the quality of instruments. However, some researchers have used 'study-specific' instruments without any validation. Such practice negates the scientific value of the published results and may discredit HRQoL assessment. It is impossible to rely on the results of studies when authors do not mention the name of the QoL instrument used: authors should always give the names of any QoL instruments used in reported studies. Where a single instrument has more than one descriptive title, the original title should be given, along with the original reference to its publication, in order to avoid confusion. Editors should ensure that published QoL data at least meet these minimum requirements. The use of modified versions of validated instruments is often described. However, such adapted questionnaires should be fully revalidated.
As the QoL impacts experienced by people aged 16-17 may differ from those experienced by children or adults, QoL measures designed for use in this age range may have advantages over both child-and adult-specific measures. 179 Although AD is Quality of life measurement in atopic dermatitis relatively uncommon in the elderly, the numbers of elderly patients with AD are gradually increasing in industrialized countries, associated with an ageing society. 180 There may be specific ways in which elderly people are affected by AD that result in specific needs: prospective research is required to address this.
It is possible to capture, with parental assistance, self-assessment of QoL in children as young as 4 years old, with the help of illustrated questionnaires. In younger children, outsider or proxy ratings can be used, but this brings with it the potential problem of adult-child concordance. 181, 182 Because of possible discrepancy between self and proxy reports, we recommend that proxy-rating questionnaires should only be used as a single measure in the youngest age group and in those patients who are unable to self-assess. Spouses can report differing views, not associated with gender. 183 Therefore, it would seem better to involve both parents in completing proxy-rated questionnaires, although this may be impractical. Cartoon versions of the questionnaires are preferable, especially for the youngest patients. Questionnaires should be selected that are appropriate for the ages of the subjects studied. If instruments have to be used out of their validated age limits, they should be revalidated.
Some reports have combined scores of the DLQI and CDLQI: such combination is inappropriate 184 as these instruments have different questions specific to the age groups for which the questionnaires are designed. The validated score banding descriptors, for example, are different. The selection of an appropriate HRQoL instrument in clinical research or practice depends on the research question and the target population in which the HRQoL instrument is administered. 185 We recommend the use of validated AD-specific instruments in addition to generic and dermatology-specific questionnaires. The use of novel instruments with limited validation and lack of validated translations may meet the needs of a local study, but such use will inevitably limit comparability and interpretation of the results in a wider context. Because of the significant family impact of AD, we recommend that family QoL should be further studied, especially concerning young children. This may help to improve clinical consultations and choice of appropriate treatment strategy. This publication has focused on the large numbers of published research studies using QoL measures in AD. However, there is virtually no information about the routine use of QoL measures in the routine management of such patients, a question that is arguably of greater practical importance to clinicians. If physicians choose to use a QoL measure in clinical practice, then issues such as simplicity of use and ability to interpret scores become of great importance.
Limitations
Because of space limitations and the high number of articles on QoL in AD, the number of references identified and reported per instrument in this paper may not reflect the actual frequency of the use of that instrument.
Conclusion
The summarized recommendations of the Task Force are presented in Table 6 and Figs 1 and 2. This study should help Epidemiological study 150 Patient perspectives 151 Self-reported skin morbidities 108 Course of life 152 Depression and anxiety in adolescent patients 67 Willingness to pay 153 Stress evaluation 154 Sleep quality 148 Mental health 155 Attachment and partnership 156 Comparison between different age groups 54 Comparison between different countries 40, 157 Gender differences 158 Pathophysiology of nocturnal scratching 159 Serum levels of heavy metals 160 Behaviour 161 Health of mothers 162 Self-image 163 Comparison of different location of lesions 164 Depression and anxiety in the caregivers of paediatric patients 165 Chemokine CCL18 166 Steroid-sparing effect 71 Impact of psychological and clinical factors 167 Actigraphy 168 Unfavourable effects of concomitant asthma 169 Effect of nurse consultation 170 Climatic change 171 Predictors of interest in patient education programmes 172 Predictors of clinical success 52 Quality of health care 173 Adherence to treatment 80 Comparison of the efficacy of nurse consultation with consultation of dermatologist 174 Time spent on treatment 175 
Table 6 Recommendations of the Task Force
Only validated QoL instruments with appropriate content should be used
The Task Forces discourage the use of HRQoL questionnaires that are altered or that are used outside their validated parameters, unless the adapted questionnaires are fully revalidated A combination of a generic-and a dermatology-specific or AD-specific instrument should be used for HRQoL assessment in clinical research, and a dermatology-specific and/or AD-specific instrument for clinical practice purposes Because of the significant family impact of AD family QoL should be further studied, especially concerning young children 
